Chesley Taft & Associates LLC Has $3.80 Million Stake in Pfizer Inc. (NYSE:PFE)

Chesley Taft & Associates LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 1.5% in the 1st quarter, Holdings Channel reports. The institutional investor owned 150,137 shares of the biopharmaceutical company’s stock after selling 2,303 shares during the period. Chesley Taft & Associates LLC’s holdings in Pfizer were worth $3,804,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter worth $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Up 0.3%

PFE opened at $23.42 on Thursday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The stock has a market capitalization of $133.15 billion, a PE ratio of 16.61, a PEG ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average price of $23.02 and a two-hundred day moving average price of $25.02.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. Pfizer’s revenue was down 7.8% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.34%. Pfizer’s payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.